Apr 30, 2019 - Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 29, 2019 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.
Apr 25, 2019 - On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.
Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Apr 10, 2019 - Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
Apr 09, 2019 - Good bargains are hard to find in today's market. Here are a few overlooked stocks for you to capitalize on.
Apr 05, 2019 - Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Apr 03, 2019 - Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.
Apr 03, 2019 - These under-the-radar stocks could be poised to make big moves in the coming months.
Apr 02, 2019 - Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.